As of June 21, 2025, Hollister Biosciences Inc (HOLL.CN) reports a Gross Margin of 1023.55%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Historical Trend of Hollister Biosciences Inc's Gross Margin
Over recent years, Hollister Biosciences Inc's Gross Margin has shown significant volatility. The table below summarizes the historical values:
| Date | Gross Margin |
|---|---|
| 2020-12-31 | 1023.55% |
| 2019-12-31 | -16.30% |
| 2018-12-31 | -135.41% |
This steady improvement highlights how Hollister Biosciences Inc manages its operational efficiency and pricing power over time.
Comparing Hollister Biosciences Inc's Gross Margin to Peers
To better understand Hollister Biosciences Inc's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| Hollister Biosciences Inc (HOLL.CN) | 1023.55% |
| Zinc8 Energy Solutions Inc (ZAIR.CN) | 7775.20% |
| Pontus Protein Ltd (HULK.V) | 7775.20% |
| Chee Corp (ECRP) | 89.99% |
| Innocan Pharma Corp (INNO.CN) | 88.96% |
| Sigyn Therapeutics Inc (SIGY) | 75.16% |
Compared to its competitors, Hollister Biosciences Inc's Gross Margin is among the highest compared to peers, indicating superior product pricing power or cost efficiency in production.